Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Consolidated revenue from operations in the quarter was marginally down at Rs 738 crore a
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
